Objective: Long-lasting control is rarely achieved with tyrosine kinase inhibitors (TKI) alone in metastatic renal cell carcinoma (mRCC). Our study aimed to investigate the survival outcomes of adding stereotactic body radiotherapy (SBRT) to TKI in mRCC. Materials and Methods: From September 2015 to September 2018, 56 patients treated with TKI received SBRT for 103 unresectable lesions. A total of 24 and 32 patients were irradiated before and after TKI failure, respectively. Overall survival (OS) was calculated from metastases. Progression-free survival (PFS) was calculated from SBRT. Results: Overall, 10, 32, and 12 patients had International Metastatic Renal Cell Carcinoma Database Consortium favorable, intermediate, and poor risk. Median follow-up was 21.7 months (range, 5.1 to 110.6 mo). Median OS was 61.2 months. The median PFS was 11.5 months, while the 2-year LC rate was 94%. Sixteen (34%) lesions achieved complete response (CR) in patients irradiated before TKI failure, whereas only 4 (7%) lesions yielded CR in those irradiated after TKI failure (P=0.001). The median PFS in CR group was significantly longer than that of non-CR group (18.9 vs. 7.1 mo; P=0.003). The 5-year OS in CR group was 86%, compared with 48% in non-CR group (P=0.010). Four (7%) patients experienced Grade 3 toxicity. Conclusions: Adding SBRT to TKI is safe and seems to improve survival in mRCC. Patients irradiated before TKI failure have higher CR rate, and the favorable local response might turn into survival benefit.

This study comparatively analysed dose distributions between the fixed and rotating gantry positions of volumetric-modulated arc therapy (VMAT) plans measured using different dosimetric techniques with the intent to provide pre-treatment quality assurance (QA). A total of 12 VMAT plans for the treatment of anatomical sites of various complexities were chosen. An ion chamber was used to measure the absolute central point doses, while EPID, Seven29, Matrixx and Delta4 were used to measure the dose distributions. With the exception of Delta4, all detectors were used in one of two different settings: the gantry was either fixed at 0°, or the gantry was rotating. The results were analysed using the γ-evaluation method. Regarding absolute central point doses, the ion chamber results were within 3% of the treatment planning system (TPS) calculated results. For the dose distributions measured by detectors and calculated by TPS, the γ pass rates, with 3% maximum dose and 3 mm γ criteria, were above 96% when the gantry was fixed at 0°. When the gantry was rotating, the pass rates decreased slightly but were still above 90%. The results obtained from the comparison between the measured and calculated doses demonstrated the reliability of four detectors associated with VMAT. However, the treatment delivery and detector response may impact the results when the gantry is rotating.

BackgroundTo evaluate the difference of absorbed doses calculated to medium and to water by a Monte Carlo (MC) algorithm based treatment planning system (TPS), and to assess the potential clinical impact to dose prescription.MethodsThirty patients, 10 nasopharyngeal cancer (NPC), 10 lung cancer and 10 bone metastases cases, were selected for this study. For each case, the treatment plan was generated using a commercial MC based TPS and dose was calculated to medium (Dm). The plan was recalculated for dose to water (Dw) using the same Monitor Units (MU) and control points. The differences between Dm and Dw were qualitatively evaluated by dose-volume parameters and by the plan subtraction method. All plans were measured using the MapCheck2, and gamma passing rates were calculated.ResultsFor NPC and Lung cases, the mean differences between Dw and Dm for the targets were less than 2% and the maximum difference was 3.9%. The maximum difference of D2% for the organs at risk (OARs) was 6.7%. The maximum differences between Dw and Dm were as high as 10% in certain high density regions. For bone metastases cases, the mean differences between Dw and Dm for the targets were more than 2.2% and the maximum difference was 7.1%. The differences between Dw and Dm for the OARs were basically negligible. At 3%&3 mm criterion, the gamma passing rate of Dw plan and Dm plan were close (> 94%).ConclusionThe differences between Dw and Dm has little clinical impact for most clinical cases. In bony structures the differences may become clinically significant if the target/OAR is receiving doses close to its tolerance limit which can potentially influence the selection or rejection of a particular plan.

Purpose In this study, we employed a gated recurrent unit (GRU)-based recurrent neural network (RNN) using dosimetric information induced by individual beam to predict the dose-volume histogram (DVH) and investigated the feasibility and usefulness of this method in biologically related models for nasopharyngeal carcinomas (NPC) treatment planning. Methods and materials One hundred patients with NPC undergoing volumetric modulated arc therapy (VMAT) between 2018 and 2019 were randomly selected for this study. All the VMAT plans were created using the Monaco treatment planning system (Elekta, Sweden) and clinically approved: > 98% of PGTVnx received the prescribed doses of 70 Gy, > 98% of PGTVnd received the prescribed doses of 66 Gy and > 98% of PCTV received 60 Gy. Of these, the data from 80 patients were used to train the GRU-RNN, and the data from the other 20 patients were used for testing. For each NPC patient, the DVHs of different organs at risk were predicted by a trained GRU-based RNN using the information given by individual conformal beams. Based on the predicted DVHs, the equivalent uniform doses (EUD) were calculated and applied as dose constraints during treatment planning optimization. The regenerated VMAT experimental plans (EPs) were evaluated by comparing them with the clinical plans (CPs). Results For the 20 test patients, the regenerated EPs guided by the GRU-RNN predictive model achieved good consistency relative to the CPs. The EPs showed better consistency in PTV dose distribution and better dose sparing for many organs at risk, and significant differences were found in the maximum/mean doses to the brainstem, brainstem PRV, spinal cord, lenses, temporal lobes, parotid glands and larynx with P-values < 0.05. On average, compared with the CPs, the maximum/mean doses to these OARs were altered by − 3.44 Gy, − 1.94 Gy, − 1.88 Gy, 0.44 Gy, 1.98 Gy, − 1.82 Gy and 2.27 Gy, respectively. In addition, significant differences were also found in brainstem and spinal cord for the dose received by 1 cc volume with 4.11 and 1.67 Gy dose reduction in EPs on average. Conclusion The GRU-RNN-based DVH prediction method was capable of accurate DVH prediction. The regenerated plans guided by the predicted EUDs were not inferior to the manual plans, had better consistency in PTVs and better dose sparing in critical OARs, indicating the usefulness and effectiveness of biologically related model in knowledge-based planning.